This quality improvement project looks at Sugammadex dosing regimens in a facility that uses qualitative assessment to assess neuromuscular recovery. To determine how dosing of Sugammadex impacts residual paralysis three dosing groups will be compared, the facility standard dosing regime of 200 mg, the manufacture recommended 2mg/kg and what recent literature recommends 1mg/kg. To determine residual paralysis tidal volume and negative inspiratory flow will be measured. This quality improvement project has the potential to reduce incidences of residual paralysis in facilities using qualitative assessment.
Read
